Inizol

Pantoprazole, the active ingredient in Inizol, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as GERD, erosive oesophagitis and Zollinger‑Ellison syndrome.

GNH USA supplies Inizol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inizol (pantoprazole) is employed to manage conditions within the acid‑related disorder pathway. - Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and relieves heartburn and regurgitation. - Erosive oesophagitis: promotes healing of inflamed esophageal tissue. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Prevention of NSAID‑induced gastric ulcers: lowers ulcer risk in patients taking NSAIDs. - Helicobacter pylori eradication (as part of combination therapy): enhances bacterial clearance when used with antibiotics.

Common Side Effects: - Headache - Diarrhea - Abdominal pain - Nausea - Flatulence - Constipation

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions - Clostridioides difficile‑associated diarrhea - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Elevated liver enzymes - Hypomagnesemia (low magnesium levels) - Acute pancreatitis

Before initiating therapy, consider the following precautions: - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor for Clostridioides difficile infection: especially in hospitalized patients. - Use caution in elderly patients: increased susceptibility to electrolyte disturbances. - Avoid abrupt discontinuation: may cause rebound acid hypersecretion. - Review concomitant medications that affect gastric pH or metabolism. - Store at room temperature: keep in the original pack, protect from moisture.

Pantoprazole may interact with several drugs; awareness of interaction severity is essential. Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - HIV protease inhibitors (e.g., ritonavir): altered plasma levels. - Methotrexate: reduced renal clearance. - Warfarin: variable INR changes.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentration. - Phenytoin: decreased plasma levels. - Carbamazepine: reduced effectiveness. - Fluconazole: increased pantoprazole exposure. - Ketoconazole: elevated ketoconazole levels.